Astrazeneca (AZN) Gains from Sales and Divestitures (2018 - 2026)

Astrazeneca's Gains from Sales and Divestitures history runs 9 years deep, the most recent figure standing at -$94.0 million for Q2 2026.

• In Q2 2026, Gains from Sales and Divestitures fell 347.62% year-over-year to -$94.0 million; the TTM figure through Jun 2026 stood at -$209.0 million (down 27.44% YoY), while the FY2025 annual figure was -$168.0 million, down 162.5% from the prior year.
• Gains from Sales and Divestitures for Q2 2026 stood at -$94.0 million, down from -$34.0 million in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was -$10.0 million in Q1 2022, with the low at -$251.0 million in Q4 2023.
• The 5-year median for Gains from Sales and Divestitures is -$64.0 million (2024), against an average of -$80.2 million.
• The sharpest annual moves came in 2022 and 2023: Gains from Sales and Divestitures soared 95.92% in 2022, then tumbled 2390.0% in 2023.
• Astrazeneca's Gains from Sales and Divestitures stood at -$88.0 million in 2022, then sank by 185.23% to -$251.0 million in 2023, then jumped by 74.5% to -$64.0 million in 2024, then climbed by 21.88% to -$50.0 million in 2025, then tumbled by 88.0% to -$94.0 million in 2026.
• Business Quant data shows AZN's Gains from Sales and Divestitures at -$94.0 million in Q2 2026, -$34.0 million in Q1 2026, and -$50.0 million in Q4 2025.